MRC1 and breast cancer: Given the fact that mismatch repair deficiency (MMRd) is associated with TMB-high status and is a validated predictive biomarker to select patients for using ICI, it was important to investigate whether it would be the major mutational process related to hypermutation in breast cancer, especially because MMR status can be assessed by the evaluation of MMR protein expression using immunohistochemistry.